Related Experiment Video
Updated: Jun 24, 2025
06:51
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
15.0K
Chimeric antigen receptor T cell therapy for autoimmune disease
James B Chung1, Jennifer N Brudno2, Dominic Borie1
1Kyverna Therapeutics Inc., Emeryville, CA, USA.
Nature Reviews. Immunology
|June 3, 2024
Summary
Chimeric antigen receptor (CAR) T-cell therapy, successful in blood cancers, shows promise for autoimmune diseases by targeting B cells. Researchers are refining CAR T-cell strategies for safer and more effective autoimmune treatment.
Area of Science:
- Immunology
- Oncology
- Rheumatology
Background:
- Chimeric antigen receptor (CAR) T-cell therapy has demonstrated significant success in treating B-cell malignancies.
- This efficacy has prompted exploration of CAR T-cell applications for autoimmune diseases characterized by aberrant immune responses.
Purpose of the Study:
- To evaluate the potential of CAR T-cell therapy in treating B-cell-driven autoimmune diseases.
- To discuss advancements and considerations for the safe and effective adoption of CAR T-cell therapy in autoimmunity.
Main Methods:
- Clinical trials involving CAR T cells targeting CD19 in patients with autoimmune diseases.
- Development of novel CAR constructs, including chimeric autoantibody receptors and antigen-specific CARs on regulatory T cells.
Main Results:
- Promising preliminary results from clinical trials using CD19-targeted CAR T cells for autoimmune conditions.
- Ongoing development of advanced CAR T-cell strategies for enhanced safety and targeted immune modulation.
Conclusions:
- CAR T-cell therapy holds significant potential for treating autoimmune diseases.
- Key considerations for clinical adoption include target cell selection, CAR design, toxicity management, and achieving lasting immune reset.
